Kaneko Kaori, Arakawa Reiko, Urano Mari, Aoki Ryoko, Saito Kayoko
Affiliated Field of Medical Genetics, Division of Biomedical Engineering and Science, Graduate Course of Medicine, Graduate School of Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Institute of Medical Genetics, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Brain Dev. 2017 Oct;39(9):763-773. doi: 10.1016/j.braindev.2017.04.018. Epub 2017 Jun 7.
To clarify the long-term natural history of SMA in Japanese patients by investigating the peak motor milestones of cases 7months through 57years of age, in efforts to contribute to evaluating outcomes of new therapeutic interventions.
We sub-classified 112 SMA type I-III cases into type Ia, type Ib, type IIa, type IIb, type IIIa and type IIIb, according to peak motor milestone achieved, and analyzed the SMN1, SMN2 and NAIP genes in relation to clinical subtypes.
In type I cases, there was a significant difference (p<0.0001), depending on whether or not head control was obtained, in the time of ventilation support being required. In type II cases as well, the time at which the ability to maintain the sitting position independently was lost also differed significantly (p<0.01) between those acquiring the ability to sit unaided within eight months after birth and those acquiring this ability after eight months of age. In type III cases, being able versus unable to climb stairs was associated with a significant difference (p=0.02) in the median time until loss of walking independently. Positive correlations were also seen between copy numbers and the clinical severity of SMA.
Our long-term results show peak motor milestone evaluations distinguishing between subtypes to be useful not only as outcome measures for assessing treatment efficacy in clinical trials but also for predicting the clinical courses of Japanese SMA patients.
通过调查7个月至57岁患者的运动发育里程碑峰值,阐明日本脊髓性肌萎缩症(SMA)患者的长期自然病史,以助力评估新治疗干预措施的效果。
我们根据达到的运动发育里程碑峰值,将112例I - III型SMA病例细分为Ia型、Ib型、IIa型、IIb型、IIIa型和IIIb型,并分析了与临床亚型相关的SMN1、SMN2和NAIP基因。
在I型病例中,根据是否获得头部控制能力,在需要通气支持的时间上存在显著差异(p<0.0001)。在II型病例中,出生后8个月内获得独立坐立能力的患者与8个月后获得该能力的患者相比,失去独立保持坐姿能力的时间也存在显著差异(p<0.01)。在III型病例中,能否爬楼梯与独立行走能力丧失前的中位时间存在显著差异(p = 0.02)。还观察到拷贝数与SMA临床严重程度之间存在正相关。
我们的长期结果表明,运动发育里程碑峰值评估区分亚型不仅对评估临床试验中的治疗效果有用,而且对预测日本SMA患者的临床病程也有用。